Effectiveness of varenicline as an aid to smoking cessation in primary care: An observational study

European Addiction Research

Volumn 19, Issue 1, 2013, Pages 47-54

  Andreas, Stefan ^a   Chenot, Jean François ^b   Diebold, Ruth ^c   Peachey, Sarah ^e   Mann, Karl ^d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c PFIZER INC   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Observational study; Primary care; Smoking cessation; Varenicline

Indexed keywords

ACETYLSALICYLIC ACID; NICOTINE; RAMIPRIL; SIMVASTATIN; TIOTROPIUM BROMIDE; VARENICLINE;

ABNORMAL DREAMING; ADULT; AGED; AGGRESSION; APATHY; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GENERAL PRACTITIONER; GERMANY; HALLUCINATION; HUMAN; HYPERTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NERVOUSNESS; OBSERVATIONAL STUDY; PANIC; PHASE 4 CLINICAL TRIAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SIDE EFFECT; SLEEP DISORDER; SMOKING CESSATION; SUICIDAL IDEATION; TOBACCO DEPENDENCE; TREATMENT DURATION; UNCONSCIOUSNESS;

EID: 85028097329     PISSN: 10226877     EISSN: 14219891     Source Type: Journal    
DOI: 10.1159/000341638     Document Type: Article

References (39)

1. Hannan EL: Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008; 1: 211-217.
2. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55.
3. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63.
4. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S: Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010; 121: 221-229.
5. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC: Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2010; 139: 591-599.
6. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al: A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012; 14: 343-350.
7. Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4: CD006103.
8. Moore TJ, Furberg CD: Varenicline and suicide. Risk of psychiatric side effects with varenicline. BMJ 2009; 339:b4964.
9. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S: Suicidal behavior and depression in smoking cessation treatments. PloS One 2011; 6:e27016.
10. Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183: 1359-1366.
11. European Medicines Agency: European Medicines Agency confirms positive benefitrisk balance for Champix. 2011. http://www. ema.europa.eu/ema/index.jsp? curl=pages/news-and-events/news/2011/07/news-detail-001314.jsp&murl=menus/ news-and-events/news-and-events.jsp&mid=WC0b 01ac058004d5c1&jsenabled= true; accessed 21 March, 2012.
12. Prochaska JJ, Hilton JF: Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012; 344:e2856.
13. Gershon AS, Warner L, Cascagnette P, Victor JC, To T: Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011; 378: 991-996.
14. Andreas S, Batra A, Behr J, Berck H, Chenot JF, Gillissen A, et al: Guidelines for smoking cessation in patients with COPD issued by the Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (in German). Pneumologie 2008; 62: 255-272.
15. Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
16. Fagard RH, Nilsson PM: Smoking and diabetes -the double health hazard! Prim Care Diabetes 2009; 3: 205-209.
17. Scallan C, Doonan RJ, Daskalopoulou SS: The combined effect of hypertension and smoking on arterial stiffness. Clin Exp Hypertens 2010; 32: 319-328.
18. Prochaska JJ: Smoking and mental illness -breaking the link. N Engl J Med 2011; 365: 196-198.
19. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al: Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
20. Lancaster T, Stead LF: Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005;2:CD001292.
21. Hughes JR, Stead LF, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031.
22. Stead LF, Perera R, Bullen C, Mant D, Lancaster T: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146.
23. Twardella D, Brenner H: Effects of practitioner education, practitioner payment and reimbursement of patients' drug costs on smoking cessation in primary care: a cluster randomised trial. Tob Control 2007; 16: 15-21.
24. Gunnell D, Irvine D, Wise L, Davies C, Martin RM: Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339:b3805.
25. Salize HJ, Merkel S, Reinhard I, Twardella D, Mann K, Brenner H: Cost-effective primary care-based strategies to improve smoking cessation: more value for money. Arch Intern Med 2009; 169: 230-235, discussion 235-236.
26. Boudrez H, Gratziou C, Messig M, Metcalfe M: Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. Curr Med Res Opin 2011; 27: 769-775.
27. West R, Hajek P, Stead L, Stapleton J: Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303.
28. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR: Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64-71.
29. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, et al: Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63: 717-724.
30. Lee JH, Jones PG, Bybee K, O'Keefe JH: A longer course of varenicline therapy improves smoking cessation rates. Prev Cardiol 2008; 11: 210-214.
31. Zeng F, Chen CI, Mastey V, Zou KH, Harnett J, Patel BV: Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clin Ther 2011; 33: 225-234.
32. Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J: A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007; 23: 793-801.
33. Halperin AC, McAfee TA, Jack LM, Catz SL, McClure JB, Deprey TM, et al: Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. J Subst Abuse Treat 2009; 36: 428-434.
34. Glassman AH, Covey LS, Stetner F, Rivelli S: Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357: 1929-1932.
35. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al: Placebocontrolled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 1193-1200.
36. World Health Organization: Global Status Report on Noncommunicable Diseases 2010; http://www.who.int/nmh/publications/ncd-report-full-en.pdf; accessed 21 March, 2012.
37. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH: Smoking and mental illness: a population-based prevalence study. JAMA 2000; 284: 2606-2610.
38. Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S: The validity of self-reported smoking: a review and metaanalysis. Am J Public Health 1994; 84: 1086-1093.
39. Becona E, Miguez MC: Concordance of selfreported abstinence and measurement of expired air carbon monoxide in a self-help smoking cessation treatment. Psychol Rep 2006; 99: 125-130.